FDA Issues CRL for Zolbetuximab in Advanced CLDN18.2+ Gastric Cancer
January 9th 2024The FDA cannot approve the application for zolbetuximab in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma due to unresolved issues following a pre-license inspection of a third-party manufacturing site.
Quiz: Detecting Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma
August 10th 2020In our liver cancer quiz, you’ll get a chance to test your knowledge on recurrence following resection in patients with intrahepatic cholangiocarcinoma and the new tools being developed to aid in treating this patient population.